<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234022</url>
  </required_header>
  <id_info>
    <org_study_id>2019HAE109</org_study_id>
    <nct_id>NCT04234022</nct_id>
  </id_info>
  <brief_title>Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma</brief_title>
  <official_title>Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Royal Wolverhampton Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wolverhampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Royal Wolverhampton Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outlook for patients with haematological malignancies remains challenging. It has been&#xD;
      shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as&#xD;
      Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in&#xD;
      clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in&#xD;
      haematological malignancies have improved outcome and survival but come with an increasing&#xD;
      cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in&#xD;
      combination with other drugs in myeloma and other haematological malignancies. This may lead&#xD;
      to potential combination therapies which will be very effective as well as affordable in the&#xD;
      future. There is the need to look to see if this drug, Imuthiol and along with complementary&#xD;
      drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological&#xD;
      malignancy treatment. In order to do this there is the need to see how the cancer cells&#xD;
      respond to the drugs in the laboratory before being able to trial the drug (or combination of&#xD;
      drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol&#xD;
      into haematological malignancy treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from&#xD;
      other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will be&#xD;
      tested.&#xD;
&#xD;
      Patients attending haematology clinics at New Cross Hospital will be reviewed for eligibility&#xD;
      of the study by the clinician and if they meet the recruitment criteria, they will be&#xD;
      approached to participate at clinic.&#xD;
&#xD;
      After informed consent, participants will be asked to donate an additional 2-3ml sample of&#xD;
      bone marrow in a single aliquot for the purpose of this study whilst undergoing a bone marrow&#xD;
      aspirate as part of their routine clinical care at diagnosis and relapse.The single aliquot&#xD;
      will be sent to the University of Wolverhampton for analysis.&#xD;
&#xD;
      Specific clincial data will be collected at the time of diagnosis and relapse:&#xD;
&#xD;
        -  Diagnosis&#xD;
&#xD;
        -  Date diagnosed&#xD;
&#xD;
        -  Disease stage&#xD;
&#xD;
        -  Relapse status&#xD;
&#xD;
        -  Age&#xD;
&#xD;
        -  Sex&#xD;
&#xD;
        -  Previous treatments&#xD;
&#xD;
        -  Date of marrow sample&#xD;
&#xD;
        -  Marrow trephine&#xD;
&#xD;
        -  Marrow liquid The clinical data set will remain at The Royal Wolverhampton NHS Trust&#xD;
           whilst analysis of the samples takes place. Once the samples have been analysed, the&#xD;
           clinical data will then be released to determine relapsed or refractory disease and&#xD;
           correlation with the in vitro data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Imuthiol and zinc efficacy</measure>
    <time_frame>7 days</time_frame>
    <description>examine the cyctotoxicity of Imuthiol and zinc in combination with other drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved</measure>
    <time_frame>7 days</time_frame>
    <description>Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Zn-DDC</arm_group_label>
    <description>samples to be exposed with Zn-DDC (Imuthiol) alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomide with Zn-DDC</arm_group_label>
    <description>samples to be exposed with Lenalidomide in combination with Zn-DDC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide with Zn-DDC</arm_group_label>
    <description>samples to be exposed with Pomalidomide in combination with Zn-DDC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zn-DDC</intervention_name>
    <description>Zn-DDC added to myeloma samples for culturing</description>
    <arm_group_label>Zn-DDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanalidomide with Zn-DDC</intervention_name>
    <description>Lanalidomide with Zn-DDC added to myeloma samples for culturing</description>
    <arm_group_label>Lenalidomide with Zn-DDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide with Zn-DDC</intervention_name>
    <description>Lanalidomide with Zn-DDC added to myeloma samples for culturing</description>
    <arm_group_label>Pomalidomide with Zn-DDC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from&#xD;
        other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will&#xD;
        be tested.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with haematological malignancy - either myeloma or acute leukaemia&#xD;
&#xD;
          -  Patients must be 18 years or over&#xD;
&#xD;
          -  Patients must be willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients will not be entered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Supratik Basu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Royal Wolverhampton NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Supratik Basu</last_name>
    <phone>01902307999</phone>
    <email>supratik.basu@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lorraine Jacques</last_name>
    <phone>01902695065</phone>
    <email>lorraine.jacques@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supratik Basu</last_name>
      <email>supratik.basu@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Stelfox</last_name>
      <email>lucy.stelfox@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Supratik Basu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

